5/10/20 individually packed test cassettes for detection of cardiac troponin I in human whole blood, serum or plasma samples
Package contents:
5/10/20 test cassettes
5/10/20 disposable pipettes
5/10/20 heparinised capillary tubes
1 buffer
1 package insert
Exclusively for professional users
Discover more than 2,000 medical and toxicological tests and POCT solutions
Please note: The prices shown are basic list prices. Your individual prices will be displayed after you have logged in to the shop. Your personal customer advisors can add them at any time.
The NADAL® Troponin I Test is a lateral flow chromatographic immunoassay for the qualitative detection of cardiac troponin I in human whole blood, serum or plasma samples. The test provides a preliminary test result as an aid in the diagnosis of myocardial infarction (MI). The NADAL® Troponin I Test is designed for professional use only. The preliminary result obtained with the NADAL® Troponin I Test should not be used for a diagnosis of exclusion of MI.
Cardiac troponin I (cTnl) is a protein found in the cardiac muscle with a molecular weight of 22.5 kDa. Troponin I is a part of a troponin complex which also includes troponin T and troponin C. Along with tropomyosin, this protein complex forms the main component that regulates the calciumsensitive ATPase activity of actomyosin in striated skeletal and cardiac muscles. Following a cardiac injury, cardiac troponin I is released into the blood 4-6 hours after the onset of pain. The release pattern of cTnl is similar to CK-MB, but whilst the CK-MB level returns to normal after 72 hours, troponin I remains elevated for 6-10 days, thus providing a longer time window for the detection of cardiac injury. The high specificity of cTnl measurements in the detection of myocardial damage has been demonstrated during surgical procedures, after marathon runs or in cases of a blunt chest trauma, amongst others. The release of cTnl has also been documented in heart conditions other than acute myocardial infarction (AMI), such as unstable angina, congestive heart failure and ischemic damage caused by coronary artery bypass surgery. Because of its high sensitivity and specificity for myocardial tissue, troponin I has recently become one of the most preferred biomarkers for myocardial infarction.
